Rezolute

RZLT

Market cap $850M

The consensus price target hints at a 56.6% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rezolute (RZLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 49.4% upside potential for Rezolute (RZLT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rezolute, Inc. ( RZLT ) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism November 10, 2025 12:00 PM EST Company Participants Christen Baglaneas Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Brian Roberts - Chief Medical Officer Sunil Karnawat Sunil Karnawat - Chief Commercial Officer Conference Call Participants Mansa Krishnamurthy Azeez Farooki Ry Forseth - Guggenheim Securities, LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Yun Zhong - Wedbush Securities Inc. Presentation Operator Good day, and welcome to the Rezolute Investor Event Conference Call. [Operator instructions].

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute.

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the three months ended September 30, 2025.

REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the company will host a virtual investor event via webcast on Monday, November 10, 2025, from 12:00 – 1:30 pm EST.

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: Maxim Growth Summit Date: October 22-23, 2025 Event: Guggenheim 2nd Annual Healthcare Innovation Conference Date: November 10-12, 2025 Event: Jefferies London Healthcare Conference Date: November 17-20, 2025 Management will be participating in one-on-one investor meetings throughout the conferences.

REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of September 30, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute.

REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025.